SOPHiA GENETICS , a leading healthcare technology firm, has announced a collaboration with Microsoft and NVIDIA to introduce an advanced whole genome sequencing (WGS) analytical solution to healthcare institutions. This partnership aims to provide a streamlined and scalable approach to genomic analysis, with the goal of delivering actionable insights to customers within the same day.
The new WGS application by SOPHiA GENETICS will offer fully analyzed whole genome insights in an accelerated timeline, empowering researchers and clinicians to make data-driven decisions rapidly. This enhanced speed not only facilitates faster diagnosis and treatment planning but also fuels innovation in clinical research and drug discovery.
Abhimanyu Verma, SOPHiA GENETICS’ Chief Technology Officer, expressed confidence in the collaboration’s ability to meet customer needs and expedite research efforts globally. Leveraging Microsoft Azure and NVIDIA’s powerful technologies, the new WGS application aims to provide accurate and scalable insights, particularly benefiting patients with rare inherited disorders.
SOPHiA GENETICS’ SOPHiA DDM™ Platform, a cloud-based Software-as-a-Service solution, serves as a universal platform enabling healthcare institutions to derive actionable insights from various data modalities. By analyzing genomic data alongside diagnostic details, imaging, pathology, and medical assessments, SOPHiA DDM™ facilitates discoveries, treatment decisions, and drug development efforts.
As part of the collaboration, SOPHiA DDM™ hosted on Azure will be powered by NVIDIA Parabricks for WGS analysis. NVIDIA Parabricks, leveraging NVIDIA accelerated computing, enables rapid processing of whole genomes in minutes, supporting diverse bioinformatics workflows with AI integration for accuracy and customization.
George Vacek, Global Head of Genomics Alliances at NVIDIA, highlighted the potential of whole-genome sequencing to enhance treatment plans and drug development efforts. The collaboration aims to unlock new possibilities and drive meaningful impact for patients worldwide.
Peter Durlach, Corporate Vice President of Health & Life Sciences at Microsoft, emphasized Microsoft’s commitment to propelling personalized medicine forward. The collaboration with SOPHiA GENETICS and NVIDIA, leveraging Azure technology, holds the potential to accelerate vital health research worldwide.
SOPHiA GENETICS continues its mission to expand access to data-driven medicine, utilizing AI to deliver world-class care to patients with cancer and rare disorders globally through its SOPHiA DDM™ Platform.
